Recruiting Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria NCT07224776 Conditions Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +11 more Locations Brigham and Women's Hospital — Boston, Massachusetts, United States View Trial Details
Recruiting A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease NCT06830629 Conditions Proteinuric Kidney Disease Locations Research Site — Decatur, Alabama, United States Research Site — Huntsville, Alabama, United States Research Site — Montgomery, Alabama, United States Research Site — Montgomery, Alabama, United States View all 79 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease NCT05312879 Conditions Proteinuric Kidney Disease Locations Alabama Kidney Research — Alabaster, Alabama, United States EmVenio Research - Mobile Unit - Birmingham — Birmingham, Alabama, United States Cardiology, P.C. — Birmingham, Alabama, United States Children's Hospital of Alabama — Birmingham, Alabama, United States View all 318 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities NCT06794996 Conditions Proteinuric Kidney Disease Locations Nephrology Consultants, LLC — Huntsville, Alabama, United States Foundation for Sickle Cell Disease Research, LLC — Hollywood, Florida, United States South Florida Research Institute — Lauderdale Lakes, Florida, United States Schiff Center for Liver Diseases — Miami, Florida, United States View all 35 locations View more locations Show fewer locations Loading locations... View Trial Details
